

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	09/851071	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:30
L2	40	Schmidt Ann Marie	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/10/31 09:32
L3	274	Stern, David	US-PGPUB; USPAT; EPO; JPO; DERWENT	NEAR	ON	2005/10/31 09:30
L4	245	Receptor SAME advanced ADJ glycation	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:47
L5	20585	RAGE	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:32
L6	143	(Receptor SAME advanced ADJ glycation) AND (cancer or tumor or mata\$10 or neoplas\$5)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/10/31 09:44
L7	74	I6 AND (amphoterin caderin integrin hyaluronic)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:43
L10	0	(Receptor SAME advanced ADJ glycation) AND (cancer or tumor or mata\$10 or neoplas\$5) AND (amphoterin caderin integrin hyaluronic)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2005/10/31 09:45
L11	186	Ruoslahti NEAR Erkki	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:47
L18	7	tumor ADJ invasion ADJ assay	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:49
L19	727	cell ADJ migration ADJ assay	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:51
L21	1	I19 and I4	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:50

L22	19	((Ruoslahti NEAR Erkki.in.) and integrin) and invasion	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:52
L25	28	I2 and I5	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:53
L26	31	I3 and I5	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:53
L29	33	I25 OR I26	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/10/31 09:54

=> d his

(FILE 'HOME' ENTERED AT 10:06:11 ON 31 OCT 2005)

FILE 'MEDLINE, CANCERLIT, AGRICOLA, CAPLUS, SCISEARCH' ENTERED AT
10:06:24 ON 31 OCT 2005

L1 5091 S RAGE OR (RECEPTOR (5W) ADVANC? (5W) GLYCATION?)
L2 138009 S EXTRACELLU? MAT?
L3 65 S L1 (L) L2
L4 8 S L3 AND PY<=1998
L5 4 DUP REM L4 (4 DUPLICATES REMOVED)
L6 4 SORT L5 PY
L7 188 S L1 (L) (AMPHOTERIN OR CADERIN OR INTERGRIN OR HYALURONIC)
L8 82 DUP REM L7 (106 DUPLICATES REMOVED)
L9 588 S L1 AND (TUMOR OR NOEPLAS? OR CANCER?)
L11 39 S L8 AND (TUMOR OR NOEPLAS? OR CANCER?)
L12 2 S L11 AND PY<=1998
L13 118 S L9 AND PY<=1998
L14 21 S L13 AND (INHIBIT? OR SPREAD? OR INVASI? OR MIGRAT?)
L15 12 DUP REM L14 (9 DUPLICATES REMOVED)
L16 12 FOCUS L15 1-
E SCHMIDT ANN?/AU
L17 188 S E1
E STERN DAVID?/AU
L18 19 S E2
L19 207 S L17 OR L18
L20 149 S L19 AND L1
L21 8 S L19 AND L3
L22 8 S L19 AND L8
L23 15 S L21 OR L22
L24 13 DUP REM L23 (2 DUPLICATES REMOVED)

L24 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:691229 CAPLUS

DN 131:317761

TI Inhibition of tumor invasion or spreading based on a soluble receptor for advanced glycation endproducts

SO PCT Int. Appl., 88 pp.

CODEN: PIXXD2

IN Schmidt, Ann Marie; Stern, David

AB The present invention provides for a method for inhibiting tumor invasion or metastasis in a subject which comprises administering to the subject a therapeutically effective amount of a form of soluble receptor for advanced glycation endproducts (RAGE).
Interruption of cellular RAGE-extracellular matrix (amphotericin and/or similar structures) interaction appears to be at least one mechanism by which sRAGE limits tumor growth. The present invention also provides a method for evaluating the ability of an agent to inhibit tumor invasion in a local cellular environment which comprises: (a) admixing with cell culture media an effective amount of the agent; (b) contacting a tumor cell in cell culture with the media from step (a); (c) determining the amount of spreading of the tumor cell culture, and (d) comparing the amount of spreading of the tumor cell culture determined in step (c) with the amount determined in the absence of the agent, thus evaluating the ability of the agent to inhibit tumor invasion in the local cellular environment. The present invention also provides a pharmaceutical composition which comprises a therapeutically effective amount of the agent evaluated in the aforementioned method and a pharmaceutically acceptable carrier.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
PI WO 9954485	A1	19991028	WO 1999-US8427	19990416
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6465422	B1	20021015	US 1998-62365	19980417
CA 2325573	AA	19991028	CA 1999-2325573	19990416
AU 9934957	A1	19991108	AU 1999-34957	19990416
EP 1071794	A1	20010131	EP 1999-916699	19990416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002512038	T2	20020423	JP 2000-544814	19990416
US 2002177550	A1	20021128	US 2001-851071	20010508



All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Books

Search PubMed



for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

- The Clipboard will hold a maximum of 500 items.
- Clipboard items will be lost after eight hours of inactivity.

About Entrez

Text Version

Display Summary



Show

20



Sort by



Send to



Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

All: 7

Review: 1



Items 1 - 7 of 7

One page.

- ☐ 1: Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM. Related Articles, Links
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.
Nature. 2000 May 18;405(6784):354-60.
PMID: 10830965 [PubMed - indexed for MEDLINE]
- ☐ 2: Hori O, Brett J, Slaterry T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, et al. Related Articles, Links
The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system.
J Biol Chem. 1995 Oct 27;270(43):25752-61.
PMID: 7592757 [PubMed - indexed for MEDLINE]
- ☐ 3: Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. Related Articles, Links
Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis.
Cancer Res. 2002 Aug 15;62(16):4805-11.
PMID: 12183440 [PubMed - indexed for MEDLINE]
- ☐ 4: Chou DK, Zhang J, Smith FI, McCaffery P, Jungalwala FB. Related Articles, Links
Developmental expression of receptor for advanced glycation end products (RAGE), amphoterin and sulfoglucuronyl (HNK-1) carbohydrate in mouse cerebellum and their role in neurite outgrowth and cell migration.
J Neurochem. 2004 Sep;90(6):1389-401.
PMID: 15341523 [PubMed - indexed for MEDLINE]
- ☐ 5: Fages C, Nolo R, Huttunen HJ, Eskelinen E, Rauvala H. Related Articles, Links
Regulation of cell migration by amphoterin.
J Cell Sci. 2000 Feb;113 (Pt 4):611-20.
PMID: 10652254 [PubMed - indexed for MEDLINE]
- ☐ 6: Kim W, Hudson BI, Moser B, Guo J, Rong LL, Lu Y, Qu W, Lalla E, Lerner S, Chen Y, Yan SS, D'Agati V, Naka Y, Ramasamy R, Herold K, Yan SF, Schmidt AM. Related Articles, Links
Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis.
Ann N Y Acad Sci. 2005 Jun;1043:553-61. Review.